Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Tscan Therapeutics Inc chart...

About the Company

harnessing novel t cell systems to extend the promise of immunotherapy

Please visit tscan.com for more information about the company.

Exchange

NASDAQ

Website

tscan.com

$109M

Total Revenue

127

Employees

$12M

Market Capitalization

-4.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TCRX News

Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%

2d ago, source:

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

1mon ago, source: Business Insider

Feb. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

22d ago, source: Hosted on MSN

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.

TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline

21d ago, source: Yahoo Finance

Warning! GuruFocus has detected 6 Warning Signs with TCRX. On March 6, 2024, TScan Therapeutics Inc (NASDAQ:TCRX) released its 8-K filing, announcing its financial results for the fourth quarter ...

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22d ago, source: Business Insider

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT an ...

TScan Therapeutics Inc TCRX

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22d ago, source: Stockhouse

March 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies ...

TCRX TScan Therapeutics, Inc.

6d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

22d ago, source: Yahoo Finance

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago. These ...

TScan Therapeutics, Inc.: TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22d ago, source: Finanznachrichten

March 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...